The HIV-Associated Lipodystrophy Treatment Market is estimated to be valued at USD 199.2 Mn in 2026 and is expected to reach approximately USD 263.0 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 4.0% from 2026 to 2033. Market growth is primarily driven by the increasing number of people receiving long-term antiretroviral therapy, rising awareness of HIV-associated fat-redistribution disorders, growing demand for pharmacological treatments such as tesamorelin, and increasing adoption of cosmetic and reconstructive procedures for managing facial lipoatrophy and abnormal fat accumulation. Improvements in HIV survival rates, greater emphasis on patients’ quality of life, and expanding access to specialized HIV care are also supporting market development.

HIV-associated lipodystrophy involves abnormal body-fat redistribution among people living with HIV and may present as lipoatrophy, characterized by the loss of subcutaneous fat, or lipoaccumulation, involving excess fat deposition in areas such as the abdomen, neck, breasts, and upper back. Treatment commonly includes growth hormones, growth hormone-releasing factor analogues, anabolic steroids, insulin-resistance modulators, metformin, thiazolidinediones, mitochondrial antioxidants, and other metabolic agents. Reconstructive procedures and injectable fillers may also be considered for patients experiencing facial lipoatrophy.

The treatment landscape is gradually shifting from the management of visible fat redistribution toward the broader management of abdominal adiposity, insulin resistance, dyslipidemia, metabolic syndrome, cardiovascular risk, and other long-term complications associated with HIV and antiretroviral therapy. This shift is increasing demand for routine metabolic assessment, body-composition monitoring, pharmacological intervention, dietary management, and multidisciplinary care involving HIV specialists, endocrinologists, nutrition professionals, dermatologists, and reconstructive surgeons.

Market Dynamics

The HIV-associated lipodystrophy treatment market is gaining momentum owing to the growing use of long-term antiretroviral therapy and the increasing prevalence of ART-related weight gain, central adiposity, insulin resistance, and other body-composition changes. As people living with HIV experience longer survival, healthcare providers are increasingly focusing on chronic metabolic and cardiovascular complications rather than limiting treatment to viral suppression and infectious-disease management.

The increasing cardiometabolic burden among people with HIV is strengthening the need for early diagnosis and intervention. Visceral-fat accumulation may be accompanied by glucose intolerance, high triglyceride levels, low HDL cholesterol, hypertension, insulin resistance, and cardiovascular complications. This is encouraging greater use of metabolic screening, abdominal-fat assessment, lifestyle modification, pharmacological treatment, and specialist referrals.

Demand for targeted therapies is also supporting market growth. Tesamorelin remains an important pharmacological treatment for reducing excess abdominal fat among adults with HIV-associated lipodystrophy. The U.S. FDA approval of EGRIFTA WR in March 2025 strengthened the availability of targeted treatment options for this patient population. However, the market remains constrained by the limited number of specifically approved therapies, high treatment costs, reimbursement barriers, and dependence on a small number of specialty products.

Emerging metabolic treatments, including GLP-1 receptor agonists, may broaden the future treatment landscape. These therapies are being investigated for their ability to reduce body weight, abdominal fat, visceral adipose tissue, and related metabolic complications among people living with HIV. Nevertheless, further HIV-specific clinical evidence and regulatory approvals will be necessary before these products become direct competitors to established lipodystrophy therapies.

The expansion of specialty-pharmacy networks is further improving access to treatment. As HIV-associated lipodystrophy is generally managed on an outpatient basis, retail and specialty pharmacies play an important role in prescription fulfilment, insurance verification, prior-authorization assistance, refill coordination, patient onboarding, and home delivery of injectable therapies.

Key Features of the Study

• This report provides in-depth analysis of the HIV-Associated Lipodystrophy Treatment Market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the HIV-Associated Lipodystrophy Treatment Market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Theratechnologies Inc., GlaxoSmithKline plc, Novelion Therapeutics Inc., AstraZeneca plc, AbbVie Inc., and Bristol-Myers Squibb.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The HIV-Associated Lipodystrophy Treatment Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the HIV-Associated Lipodystrophy Treatment Market

Market Segmentation

• By Lipodystrophy Type (Revenue, USD Mn, 2021-2033)
  • Lipoatrophy
  • Lipoaccumulation
• By Therapeutic Class (Revenue, USD Mn, 2021-2033)
  • Anabolism modulators
  • Growth hormones
  • Anabolic steroids
  • Insulin resistance modulators
  • Metformins
  • Thiazolidinediones
  • Mitochondrial antioxidants (l-carnitine)
  • Miscellaneous metabolic agents
• By Distribution Channel (Revenue, USD Mn, 2021-2033)
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
• By Region (Revenue, USD Mn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Key Players
  • Theratechnologies Inc.
  • GlaxoSmithKline plc
  • Novelion Therapeutics Inc.
  • AstraZeneca plc
  • AbbVie Inc.
  • Bristol-Myers Squibb